M&A: Cureety Acquires Reimagine Care to Expand Precision Oncology Platform Across 250 Cancer Centers
CureetyAcquirer
Cureety, the Paris‑based precision oncology SaaS provider, has acquired Nashville‑based Reimagine Care, adding conversational AI and virtual nursing to its platform. The combined business now supports more than 250 cancer centers and 100,000 patients across five countries, operating profitably with roughly 150 staff. Financial terms were not disclosed.
Deal Terms
Cureety announced the acquisition of Reimagine Care on September 2, 2026. The transaction, whose financial details were not disclosed, creates a single digital oncology organization that is already profitable and employs about 150 people. Together the firms serve over 250 cancer centers and roughly 100,000 patients in five countries.
Strategic Rationale
Cureety’s core offering is a therapy‑specific clinical triage engine that matches patient‑reported outcomes to the toxicity profile of each regimen. Reimagine Care contributes Remi, an AI‑driven conversational agent backed by a 24/7 team of oncology‑trained nurses. By embedding Remi into Cureety’s workflow, the combined platform can resolve up to 95% of routine outpatient inquiries virtually while escalating true emergencies to human clinicians.
The acquisition addresses three operational pressures facing community oncology practices. First, it provides continuous monitoring needed for high‑complexity cellular therapies such as CAR‑T and bispecific antibodies, enabling these treatments to be administered outside academic centers. Second, the integrated solution maps directly to Medicare and commercial reimbursement streams, including Remote Patient Monitoring (RPM) and Principal Care Management (PCM). Third, the platform generates longitudinal real‑world evidence for biopharma sponsors, capturing safety endpoints and toxicity progression during clinical trials.
Cureety’s CEO François‑Guirec Champoiseau emphasized that the deal brings “the same level of precision to the care surrounding” advanced cancer therapies. The merged entity now offers a unified stack that couples algorithmic triage with AI‑enabled patient engagement, positioning it as a comprehensive SaaS solution for oncology providers seeking to scale high‑touch care without proportionally expanding staff.
Market Implications
The move expands Cureety’s geographic footprint into the United States and deepens its presence in Europe, while also adding a robust virtual care capability that many pure‑play triage platforms lack. Competitors that focus solely on data analytics or on telehealth will need to consider broader, end‑to‑end solutions to stay relevant in the rapidly evolving precision‑oncology market.
Overall, the acquisition creates a scalable, revenue‑generating engine that can capture additional reimbursement streams, support the rollout of next‑generation therapies, and deliver actionable real‑world data to drug developers.
Why It Matters
For Cureety, the acquisition instantly broadens its addressable market by adding a proven AI engagement layer and a 24/7 clinical support team, allowing it to sell a more complete solution to health systems that are under pressure to monitor complex therapies at scale. Reimagine Care gains access to Cureety’s extensive oncology network and algorithmic triage engine, accelerating its path to profitability and expanding its footprint beyond the U.S.
Direct competitors that currently offer either AI‑driven patient engagement or therapy‑specific triage now face a combined platform that can lock in both reimbursement streams and data‑capture capabilities. Those rivals will likely need to pursue similar integrations or partnerships to avoid losing market share in community oncology settings that are increasingly adopting digital care pathways.
Key Points
- Cureety acquired Reimagine Care, merging AI patient engagement with therapy‑specific triage
- The combined entity serves over 250 cancer centers and 100,000 patients across five countries
- Remi, Reimagine Care’s conversational AI, resolves up to 95% of routine outpatient concerns virtually
- The transaction creates a profitable organization with roughly 150 employees
- Financial terms of the deal were not disclosed
Analysis
The Cureety‑Reimagine Care deal illustrates how precision‑oncology SaaS firms are moving beyond data analytics toward full‑stack care delivery. By bundling algorithmic triage with an AI‑powered virtual nursing layer, the combined platform can capture additional revenue streams such as Remote Patient Monitoring and Principal Care Management, which are increasingly reimbursed under Medicare and commercial plans. This creates a higher ARR ceiling and improves net revenue retention as providers adopt the solution for both routine monitoring and high‑complexity cellular therapies. The integration also strengthens the company’s ability to generate longitudinal real‑world evidence, a valuable asset for biopharma partners seeking safety and efficacy signals. For investors, the transaction signals that valuation multiples for end‑to‑end oncology SaaS platforms may command a premium over narrower data‑only playbooks, especially as health systems prioritize scalable, reimbursable virtual care models. Operators should anticipate tighter competition on both the AI engagement and triage fronts, prompting further M&A activity aimed at consolidating the fragmented digital oncology market.